An update on TroVax® for the treatment of progressive castration-resistant prostate cancer

被引：3

作者：

Abern, Michael ^{[2
]}

Kaufman, Howard L. ^{[1
]}

Latchamsetty, Kalyan ^{[2
]}

机构：

[1] Rush Univ, Med Ctr, Dept Gen Surg & Immunol & Microbiol, Chicago, IL 60612 USA

[2] Rush Univ, Med Ctr, Dept Urol, Chicago, IL 60612 USA

来源：

ONCOTARGETS AND THERAPY | 2011年 / 4卷

关键词：

castration resistance; prostate cancer; TroVax; vaccine; ANTIGEN; 5T4; TROVAX; MITOXANTRONE PLUS PREDNISONE; POTENT IMMUNE-RESPONSES; METASTATIC RENAL-CANCER; CONTROLLED PHASE-III; SIPULEUCEL-T; CELLULAR IMMUNOTHERAPY; INTERFERON-ALPHA; SOLID TUMORS; DOUBLE-BLIND;

D O I：

10.2147/OTT.S14271

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Prostate cancer is a common human malignancy with few effective therapeutic options for treating advanced castration-resistant disease. The potential therapeutic effectiveness of immunotherapy and vaccines, in particular, has gained popularity based on the identification of prostate-associated antigens, potent expression vectors for vaccination, and data from recent clinical trials. A modified vaccinia Ankara (MVA) virus expressing 5T4, a tumor-associated glycoprotein, has shown promise in preclinical studies and clinical trials in patients with colorectal and renal cell carcinoma. This review will discuss the rationale for immunotherapy in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the MVA-5T4 (TroVax (R)) vaccine.

引用

页码：33 / 41

页数：9

共 61 条

[1]

Altekruse S F., SEER CANC STAT REV 1

[2]

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial [J].

Amato, Robert J. ;

Shingler, William ;

Naylor, Stuart ;

Jac, Jaroslaw ;

Willis, James ;

Saxena, Somyata ;

Hernandez-McClain, Joan ;

Harrop, Richard .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7504-7510

[3]

Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) - A phase 2 trial [J].

Amato, Robert J. ;

Drury, Noel ;

Naylor, Stuart ;

Jac, Jaroslaw ;

Saxena, Somya ;

Cao, Amy ;

Hernandez-McClain, Joan ;

Harrop, Richard .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (06) :577-585

[4]

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study [J].

Amato, Robert J. ;

Hawkins, Robert E. ;

Kaufman, Howard L. ;

Thompson, John A. ;

Tomczak, Piotr ;

Szczylik, Cezary ;

McDonald, Mike ;

Eastty, Sarah ;

Shingler, William H. ;

de Belin, Jackie ;

Goonewardena, Madusha ;

Naylor, Stuart ;

Harrop, Richard .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5539-5547

[5]

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α) A Phase 2 Trial [J].

Amato, Robert J. ;

Shingler, William ;

Goonewardena, Madusha ;

de Belin, Jackie ;

Naylor, Stuart ;

Jac, Jaroslaw ;

Willis, James ;

Saxena, Somyata ;

Hernandez-McClain, Joan ;

Harrop, Richard .

JOURNAL OF IMMUNOTHERAPY, 2009, 32 (07) :765-772

[6]

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Soban, Freidele ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245

[7]

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].

Blanchard, TJ ;

Alcamí, A ;

Andrea, P ;

Smith, GL .

JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167

[8]

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line [J].

Carroll, MW ;

Moss, B .

VIROLOGY, 1997, 238 (02) :198-211

[9]

Carsberg CJ, 1996, INT J CANCER, V68, P84, DOI 10.1002/(SICI)1097-0215(19960927)68:1<84::AID-IJC15>3.0.CO

[10]

2-6

← 1 2 3 4 5 6 7 →